glp3.wiki
Investigational · not FDA approved

Editorially reviewed · Last updated September 8, 2026 · How we review

Retatrutide Results: Before and After — What the Data Actually Shows

Part of Find a retatrutide clinical trial.

Retatrutide Results: Before and After — What the Data Actually Shows

A retatrutide before-and-after photo can show a change in appearance. It cannot establish what someone took, how much weight was fat rather than lean tissue, or whether the result is typical. This page uses published trial measurements rather than presenting unverified photographs as clinical proof.

The strongest comparisons are within the same randomized trial, at a stated dose and timepoint. The figures below are group results, not a month-by-month prediction for an individual. Retatrutide remains investigational.

Weight Loss Over Time

Phase 2 Trial (48 Weeks, 338 Participants)

Swipe sideways to see every column.

Timepoint12 mg8 mg4 mgPlacebo
Week 24-17.5%-17.3%-12.9%-1.6%
Week 48-24.2%-22.8%-17.1%-2.1%

The 4 mg and 8 mg Phase 2 values pool the different starting-dose groups.

Phase 3 TRIUMPH-4 (68 Weeks, 445 Participants)

Swipe sideways to see every column.

Timepoint12 mg9 mgPlacebo
Week 68 (~16 months)-28.7%-26.4%-2.1%
These TRIUMPH-4 values use the efficacy estimand, which estimates results had participants remained on treatment without prohibited weight-management therapy. The treatment-regimen estimate, regardless of adherence, was 23.7% at 12 mg versus 4.6% with placebo. Participants had obesity or overweight and knee osteoarthritis, without diabetes.

What This Looks Like in Practice

An average percentage does not give an individual's future weight. It also does not show how many people stopped treatment. In TRIUMPH-4, 18.2% of the 12 mg group discontinued because of adverse events, compared with 4.0% of the placebo group.

For a fuller picture, compare the mean, the responder percentages below, and tolerability. Do not interpolate a trial's week-68 result into a first-month or third-month target.

Expected Timeline

The Phase 2 trial measured the main weight endpoints at weeks 24 and 48. Its average curves had not clearly plateaued by week 48, but that does not mean every participant kept losing weight or that weight loss continues indefinitely.

Later TRIUMPH-1 results provide another defined timepoint: 28.3% mean weight loss at 12 mg at week 80, using the efficacy estimand. Differences between studies do not form one continuous weight-loss curve. See all trial results for the populations and analysis methods.

Milestone Achievement Rates

What percentage of participants reached each weight loss threshold (12 mg dose):

Phase 3 (TRIUMPH-4, 68 Weeks)

Swipe sideways to see every column.

Threshold12 mg9 mgPlacebo
Lost at least 25%58.6%47.7%1.3%
Lost at least 30%39.4%30.5%0.8%
Lost at least 35%23.7%18.2%0.0%

These are efficacy-estimand results. The 30% and 35% analyses were not controlled for multiplicity, so they need more caution than the prespecified primary endpoints.

Phase 2 (48 Weeks)

Swipe sideways to see every column.

Threshold12 mg8 mg (pooled)4 mg (pooled)
Lost at least 5%100%100%92%
Lost at least 10%93%91%75%
Lost at least 15%83%75%60%

These figures describe the trial's reported endpoint estimates. They do not guarantee response in every future user or establish that an online product will reproduce them.

Who Responds Best

Based on Phase 2 sub-analyses:

  • Women showed larger percentage reductions in body weight than men
  • Higher baseline BMI correlated with greater percentage weight loss
  • These subgroup patterns do not predict an individual response
  • The 12 mg dose consistently produced better results than lower doses, but even the 4 mg dose achieved ~17% weight loss

Beyond the Scale: Other Changes

Other endpoints come from different studies, so they should not be treated as one person's expected package of benefits:
  • Liver fat: the Phase 2 MASLD substudy reported an 82.4% relative reduction at 12 mg at week 24, measured by MRI. This is not the same as reversing liver scarring.
  • Blood pressure: TRIUMPH-4 reported a 14.0 mmHg systolic reduction at 12 mg at week 68 under the efficacy estimand.
  • HbA1c: the Phase 2 type 2 diabetes trial reported a 2.02 percentage-point reduction at 12 mg at week 24.
  • Knee pain: TRIUMPH-4 reported a 4.4-point WOMAC pain reduction at 12 mg at week 68. Its 74.3% relative reduction came from a post-hoc analysis.

How Retatrutide Results Compare

TRIUMPH-5 is directly comparing retatrutide with tirzepatide. Its registry has no posted results at this review. Until that comparison is available, retatrutide's Phase 2 and TRIUMPH results should not be ranked against another drug by simply placing percentages from different populations side by side.

For the existing comparative evidence, see retatrutide versus tirzepatide and retatrutide versus Wegovy.

Frequently Asked Questions

Are there real before-and-after photos of retatrutide?

This page has not independently authenticated social-media photos or their drug histories. A photograph cannot establish product identity, causation or typical results. Use trial measurements for evidence and treat personal transformations as individual accounts.

How much weight can I expect to lose on retatrutide?

In TRIUMPH-4, the 12 mg group had 28.7% mean weight loss at week 68 under the efficacy estimand and 23.7% under the treatment-regimen estimand. These are study estimates for adults with obesity or overweight and knee osteoarthritis, not a personal forecast.

When does weight loss start?

The trial results do not establish a universal start date or weekly target. Early appetite changes and scale changes are different outcomes. Do not use a lack of immediate change as a reason to alter an investigational regimen.

Does weight loss plateau?

The average Phase 2 curve had not clearly plateaued at 48 weeks. This does not rule out individual plateaus or show that loss continues indefinitely. Longer studies must be interpreted using their own populations and endpoints.

What happens to muscle mass?

In the 36-week substudy in adults with type 2 diabetes, total fat mass fell by 26.1% in the pooled 8 mg group and 23.2% at 12 mg. Lean mass also declined; it is not the same measurement as skeletal muscle alone. Only 103 of 189 substudy participants completed treatment and both DXA scans. See muscle-loss evidence.

Sources

How we keep this honest
What this is
Educational information, not medical advice. It reports published research — it doesn’t recommend that you use, obtain, or supply anything.
Regulatory status
Retatrutide and similar peptides are investigational — not approved by the FDA or any regulator. Semaglutide and tirzepatide are prescription-only medicines, available only through a licensed prescriber.
Our standard
Every claim traces to a primary source. We label the strength of evidence and flag estimates as estimates — never as clinical fact.
No commercial ties
We don’t sell, supply, or link to suppliers of any medicine, and aren’t affiliated with any manufacturer.

Do not make decisions about your health without consulting a qualified healthcare provider. For trial enrolment, see ClinicalTrials.gov. More on how we review.

Grounded in primary sources
NEJMThe LancetJAMAFDAClinicalTrials.gov

Keep exploring

Explore all trials & fda topics →